See the DrugPatentWatch profile for cosentyx

There is currently no definitive scientific evidence or studies suggesting a direct connection between Cosentyx and reduced vaccine potency at injection sites. Cosentyx, also known as secukinumab, is a medication used to treat various autoimmune conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a monoclonal antibody that targets interleukin-17A (IL-17A), a protein involved in inflammation [1].

Vaccine potency may be affected by various factors, including the individual's immune system, vaccine formulation, storage conditions, and administration technique [2]. Since Cosentyx works by modulating the immune system, it is essential to consider its potential impact on vaccine efficacy. However, the available information does not specifically address the interaction between Cosentyx and vaccine potency at injection sites [1].

It is important to consult healthcare professionals for personalized advice on vaccinations and medication management. They can provide guidance based on the individual's medical history, current medications, and vaccine requirements [2].

In summary, based on the available information, there is no concrete evidence linking Cosentyx to reduced vaccine potency at injection sites. However, it is always advisable to consult healthcare professionals for personalized advice on vaccinations and medication management.

Sources:
[1] DrugPatentWatch.com. Cosentyx (secukinumab). <https://www.drugpatentwatch.com/drugs/cosentyx>
[2] Centers for Disease Control and Prevention. Vaccine Administration. <https://www.cdc.gov/vaccines/hcp/admin/admin-basics.html>